Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Oblenio Bio
Oblenio Bio

Oblenio Bio

Series B

Oblenio Bio develops antibody therapies for autoimmune diseases.

HQ
Cambridge, MA, US
Founded
2024
Overview
Compare
Fundraising
Employees
News

Oblenio Bio is a biotechnology company developing therapies for autoimmune diseases. Its lead program is a tri-specific T-cell engager intended to address disease biology through targeted immune modulation.

The company closed a $62 million Series B financing in June 2026 to advance its autoimmune pipeline. Public announcements describe Oblenio Bio as based in Cambridge, Massachusetts, with origins in Aditum Bio and Leads Biolabs.

Oblenio Bio - Similar Companies

GentiBio logo

GentiBio

gentibio.com

iBio logo

iBio

ibioinc.com

RenBio logo

RenBio

renbio.com

Dren Bio logo

Dren Bio

drenbio.com

Global Bio logo

Global Bio

HI-Bio logo

HI-Bio

hibio.com

BLR Bio logo

BLR Bio

blrbio.com

Q32 Bio logo

Q32 Bio

q32bio.com

100Xbio logo

100Xbio

100xbio.com

Aibios logo

Aibios

aibios.com

Tolerion logo

Tolerion

Upstream Bio logo

Upstream Bio

upstreambio.com

Orion BioScience logo

Orion BioScience

Triveni Bio logo

Triveni Bio

triveni.bio

Arranta Bio logo

Arranta Bio

Oblenio Bio - Quick Facts

Who are Oblenio Bio's competitors?

Companies similar to Oblenio Bio include GentiBio, iBio, RenBio and Dren Bio.

When was Oblenio Bio founded?

Oblenio Bio was founded in 2024.

Where is Oblenio Bio's headquarters located?

Oblenio Bio's headquarters is located in Cambridge, MA, US.

When was Oblenio Bio's last funding round?

Oblenio Bio's most recent funding round was for $62M (USD) in June 2026.

How much has Oblenio Bio raised to-date?

As of Jun 25, 2026, Oblenio Bio has raised a total of $62M (USD).

Oblenio Bio - Classification

Industry
  • Biotechnology